Earnings summaries and quarterly performance for TEVA PHARMACEUTICAL INDUSTRIES.
Executive leadership at TEVA PHARMACEUTICAL INDUSTRIES.
Richard D. Francis
Detailed
President and Chief Executive Officer
CEO
CF
Chris Fox
Detailed
Executive Vice President, North America Commercial
DM
David McAvoy
Detailed
Executive Vice President, Chief Legal Officer
EK
Eli Kalif
Detailed
Executive Vice President, Chief Financial Officer
EH
Eric Hughes
Detailed
Executive Vice President, Global R&D and Chief Medical Officer
EL
Evan Lippman
Detailed
Executive Vice President, Business Development
MS
Mark Sabag
Detailed
Executive Vice President, International Markets Commercial
MS
Matthew Shields
Detailed
Executive Vice President, Teva Global Operations
PJ
Placid Jover
Detailed
Executive Vice President, Chief Human Resources Officer
RD
Richard Daniell
Detailed
Executive Vice President, European Commercial
Board of directors at TEVA PHARMACEUTICAL INDUSTRIES.
AE
Amir Elstein
Detailed
Director
CL
Chen Lichtenstein
Detailed
Director
GM
Gerald M. Lieberman
Detailed
Director
JS
Janet S. Vergis
Detailed
Director
PD
Perry D. Nisen
Detailed
Director
RA
Roberto A. Mignone
Detailed
Director
RS
Ronit Satchi-Fainaro
Detailed
Director
RA
Rosemary A. Crane
Detailed
Director
SJ
Sol J. Barer
Detailed
Chairman of the Board
TZ
Tal Zaks
Detailed
Director
VS
Varda Shalev
Detailed
Director
Research analysts who have asked questions during TEVA PHARMACEUTICAL INDUSTRIES earnings calls.
David Amsellem
Piper Sandler Companies
3 questions for TEVA
Also covers: ABBV, ALKS, AMGN +27 more
Jason Gerberry
Bank of America Merrill Lynch
3 questions for TEVA
Also covers: ALKS, AMPH, ARWR +21 more
UR
Umer Raffat
Evercore ISI
3 questions for TEVA
Also covers: ALKS, AMGN, BHC +15 more
AV
Ashwani Verma
UBS Group AG
2 questions for TEVA
Also covers: ACAD, ALKS, ALVO +12 more
CS
Chris Schott
JPMorgan Chase & Company
2 questions for TEVA
Also covers: IDXX, JNJ
DD
Dennis Ding
Jefferies Financial Group Inc.
2 questions for TEVA
Also covers: ARDX, CARA, FOLD +6 more
LS
Les Sulewski
Truist
2 questions for TEVA
Also covers: CRMD
LC
Louise Chen
Cantor Fitzgerald
2 questions for TEVA
Also covers: ARDX, CNTB, IMAB +15 more
AV
Ash Verma
UBS
1 question for TEVA
Also covers: ALVO, AVDL, EXEL +6 more
CS
Christopher Schott
JPMorgan Chase & Co.
1 question for TEVA
Also covers: ABBV, AMGN, AMRX +15 more
Keonhee Kim
Morningstar, Inc.
1 question for TEVA
LS
Leszek Sulewski
Truist Securities
1 question for TEVA
Also covers: AKBA, AMRX, ANIP +6 more
MD
Matthew Dellatorre
Goldman Sachs Group Inc.
1 question for TEVA
Also covers: AMRX, INCY
UR
Umer Rappat
Evercore ISI
1 question for TEVA
Recent press releases and 8-K filings for TEVA.
Teva Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook
TEVA
Earnings
Guidance Update
New Projects/Investments
- Teva reported Q4 2025 revenue of approximately $4.2 billion and non-GAAP EPS of $0.68, with full-year 2025 free cash flow reaching $1.9 billion (excluding a development milestone). The company's net debt to EBITDA ratio stood at 2.5x at year-end 2025.
- The innovative portfolio, including AUSTEDO, UZEDY, and AJOVY, demonstrated strong growth, surpassing $1 billion in Q4 2025 sales. AUSTEDO achieved $2.2 billion in full-year sales, UZEDY $191 million, and AJOVY $673 million.
- For 2026, Teva expects full-year revenue between $16.4 billion and $16.8 billion, non-GAAP EPS in the range of $2.57 to $2.77, and free cash flow between $2 billion and $2.4 billion.
- The company made significant progress on its transformation program, achieving $70 million in savings in 2025 and remaining on track to deliver $700 million in savings by 2027.
- Key pipeline advancements include the initiation of a Phase 3 study for duvakitug in UC and CD, which triggered a $500 million milestone payment in Q4 2025 , and expected results for the Anti-IL-15 program in vitiligo in the first half of 2026.
6 days ago
Teva Pharmaceutical Industries Ltd. Reports Q4 and Full-Year 2025 Results, Provides 2026 Outlook
TEVA
Earnings
Guidance Update
New Projects/Investments
- Teva reported Q4 2025 revenue of approximately $4.2 billion and non-GAAP EPS of $0.68. For the full year 2025, EBITDA grew 12% to $5.3 billion, EPS grew 19% to $2.93, and free cash flow was $2.4 billion including milestone payments.
- The company's innovative portfolio, including AUSTEDO ($2.26 billion, up 34%), UZEDY ($191 million, up 63%), and AJOVY ($673 million, up 30%), drove significant growth, surpassing $1 billion in Q4 2025.
- For 2026, Teva expects full-year revenue between $16.4 billion and $16.8 billion, non-GAAP EPS in the range of $2.57 to $2.77, and free cash flow between $2 billion and $2.4 billion.
- Teva is on track to achieve $700 million in net savings by 2027 from its transformation program, having achieved $70 million in 2025. Key pipeline milestones for 2026 include anticipated approval of Olanzapine LAI and maintenance data for Duvakitug.
6 days ago
Teva Reports Q4 and Full-Year 2025 Results, Provides 2026 Outlook
TEVA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Teva reported Q4 2025 revenue of $4.2 billion and non-GAAP EPS of $0.68, with full-year 2025 free cash flow reaching $1.9 billion, all figures excluding a $500 million Sanofi milestone payment and Japan Business Venture contributions.
- The company's innovative portfolio, including AUSTEDO ($2.2 billion, up 35%), UZEDY ($191 million, up 63%), and AJOVY ($673 million, up 30%), drove significant growth in 2025, with the total innovative portfolio reaching $3.1 billion for the year.
- For 2026, Teva expects revenue between $16.4 billion and $16.8 billion, and non-GAAP EPS in the range of $2.57 to $2.77, with free cash flow projected at $2 billion to $2.4 billion.
- Teva is on track to achieve $700 million in transformation program savings by 2027 and aims for a net debt to EBITDA ratio of 2.0x by 2027, having reached 2.5x in Q4 2025.
- Key pipeline developments include the initiation of Phase 3 for duvakitug in Q4 2025, triggering a $500 million milestone payment from Sanofi, and the anticipated approval of olanzapine LAI by the end of 2026.
6 days ago
Teva Reports Third Consecutive Year of Growth in 2025, Driven by Innovative Portfolio
TEVA
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Teva reported its third consecutive year of growth in 2025, with full-year revenues reaching $17.3 billion and Q4 2025 revenues at $4.7 billion.
- Growth was significantly driven by key innovative brands (AUSTEDO, AJOVY, UZEDY), which collectively generated over $3 billion in revenues for 2025 (up 35% YoY in LC) and approximately $1 billion in Q4 2025.
- For FY 2025, Teva achieved Non-GAAP diluted EPS of $2.93 and free cash flow of $2,396 million, while reducing gross debt to $16.8 billion by December 31, 2025.
- The company provided a 2026 outlook, projecting revenues between $16.4 - $16.8 billion, Non-GAAP diluted EPS of $2.57 - $2.77, and free cash flow of $2.0 - $2.4 billion.
- Teva is advancing its innovative late-stage pipeline, targeting 4 product submissions over the next 5 years, including the NDA for olanzapine LAI submitted in December 2025.
6 days ago
Teva Pharmaceuticals Updates on "Pivot to Growth" Strategy and Pipeline
TEVA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Teva Pharmaceuticals is executing a "pivot to growth" strategy, transitioning to a biopharma company, and has achieved 11 consecutive quarters of growth since early 2023.
- Despite an anticipated $1.1 billion loss in generic Revlimid revenue in 2026, the company expects continued growth in EBITDA, operating margin, and free cash flow, aiming for a 30% operating margin by 2027 and net debt below two times.
- The innovative business revenue has doubled in the last three years, with a pipeline projected to generate over $10 billion in peak sales from products like Austedo, Ajovy, Uzedy, and late-stage assets such as Duvakitug and anti-IL-15. Royalty Pharma has invested $500 million in the anti-IL-15 asset.
Jan 13, 2026, 4:15 PM
Teva Outlines "Pivot to Growth" Strategy and Pipeline at J.P. Morgan Healthcare Conference
TEVA
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- Teva's "pivot to growth strategy," launched three years ago, has successfully transformed the company towards a biopharma focus, achieving 11 consecutive quarters of growth since the start of 2023.
- The company projects its innovative business to achieve over $10 billion in peak sales from its pipeline, with key products like Austedo, Ajovy, and Uzedy expected to reach $3 billion, $1 billion, and $1.5-$2 billion respectively.
- Teva anticipates a $1.1 billion loss in generic Revlimid revenue, forecasting zero revenue from it in 2026, which will result in a flat to slightly down overall revenue outlook for the year despite strong innovative growth.
- Significant pipeline data readouts are expected throughout 2026, including maintenance data for Duvakitug, vitiligo and celiac disease data for anti-IL-15, and futility analysis for Anle138b.
Jan 13, 2026, 4:15 PM
Teva Pharmaceutical Industries Highlights Biopharma Transformation and Future Growth Drivers
TEVA
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Teva Pharmaceutical Industries has executed a "pivot to growth" strategy over the past three years, transforming into a biopharma company and achieving 11 consecutive quarters of growth since the start of 2023. This transformation is driving consistently growing revenue, increasing gross margin, free cash flow, EBITDA, operating margin, and earnings per share, alongside debt reduction.
- The company's innovative product portfolio has shown strong performance, with Austedo's revenue more than doubling in three years and peak sales expectations rising to potentially $3 billion. Ajovy is projected to reach $1 billion in sales, and Uzedy is the fastest-growing schizophrenia treatment, with an expected $1.5-$2 billion in peak sales, soon to be complemented by a long-acting Olanzapine.
- Teva's late-stage pipeline is anticipated to generate over $10 billion in peak sales and includes plans to launch a new product almost every year. Key upcoming launches and data readouts include Olanzapine this year, DARI in 2027, and significant data for Duvakitug (Q1 2026), Anle138b (mid-2026), and anti-IL-15 (H1 and H2 2026).
- Despite the loss of $1.1 billion in generic Revlimid revenue in 2026, Teva expects its top-line revenue to be flat to slightly down, while continuing to grow EBITDA, operating margin, and free cash flow, aiming for a 30% operating margin in 2027 and achieving an investment-grade debt rating.
Jan 13, 2026, 4:15 PM
Teva Pharmaceutical Industries Ltd. Announces 2025 Performance Expectations and Long-Term Outlook
TEVA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Teva Pharmaceutical Industries Ltd. will present its expected 2025 financial performance and forward-looking outlook for 2026 and beyond at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
- For 2025, Teva expects Revenues at the lower point of the $16.8 - $17.0 billion range, with an additional $500 million from duvakitug milestones. The company also anticipates Adjusted EBITDA at the midpoint of the $4.8 - $5.0 billion range, plus ~$400M-$430M from duvakitug milestones.
- Teva projects Diluted EPS at the higher point of the $2.55 - $2.65 range for 2025.
- The company expects Free Cash Flow to be at the higher point of the $1.6 - $1.9 billion range for 2025, with an additional ~$500M from duvakitug milestones, and forecasts it to grow to >$2.7 billion by 2027 and >$3.5 billion by 2030.
- Teva is accelerating its "Pivot to Growth" strategy, focusing on transforming into a leading innovative biopharmaceutical company, and aims to achieve Net Leverage of <2x by 2027 and 2030, committing to securing an investment-grade credit rating.
Jan 12, 2026, 11:00 AM
Teva Extends Revolving Credit Maturity and Amends Financial Covenants
TEVA
Debt Issuance
M&A
- Teva Pharmaceutical Industries Limited extended the stated maturity date of its Senior Unsecured Sustainability-Linked Revolving Credit Agreement from April 29, 2027 to April 29, 2028. This marks the second such extension.
- The company amended its financial covenants, setting the maximum permitted leverage ratio for Q4 2025 and thereafter at 4.25x. This ratio can increase by 0.5x for up to three consecutive quarters if the company undertakes certain material transactions, such as acquisitions or substantial investments.
- A new provision allows for the suspension of the maximum leverage ratio and minimum interest cover ratio covenants if Teva achieves Investment Grade Status and no Event of Default is continuing. These covenants would be reinstated if Investment Grade Status is lost or an Event of Default occurs.
Dec 11, 2025, 9:31 PM
Teva Details "Pivot to Growth" Strategy and Pipeline at Citi Conference
TEVA
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- Teva is actively transitioning from a leading generics company to a biopharma company under its "Pivot to Growth" strategy, demonstrating significant progress over the past three years.
- The company projects to grow its EBITDA in the upcoming year, despite an anticipated loss of over $1 billion from generic Revlimid sales, driven by strong performance from innovative products like Austedo (with projected peak sales exceeding $3 billion) and Uzedy, alongside $500 million in cost savings by the end of 2026.
- Teva expects its gross margin to continuously expand, reaching 57%-58% by 2027 and continuing through 2032, primarily due to the increasing contribution of higher-margin innovative products from its pipeline.
- Upcoming key product launches include Olanzapine (a long-acting schizophrenia product, launching end of Q3/Q4 next year, contributing to a $1.5-$2 billion schizophrenia franchise) and Duvakitug TL1A (a Phase 3 asset for UC/CD, projected as a $3-$5 billion product with Teva holding 50% economics, launching in 2029).
Dec 4, 2025, 3:30 PM
Fintool News
In-depth analysis and coverage of TEVA PHARMACEUTICAL INDUSTRIES.
Quarterly earnings call transcripts for TEVA PHARMACEUTICAL INDUSTRIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more